The stock of PDL BioPharma Inc. (PDLI) increased by 0.83% to finish the standard trading session at $2.43. During that period, a total of 744913 shares were traded, and this stock’s average trading volume is currently 1.18M shares per day. Important things to pay attention to when considering a stock’s current and future price are the 52-week high and low price points. Shares of PDL BioPharma Inc. (PDLI) are currently -30.54% below their 52-week high mark and 36.92% higher than the 52-week low mark.
Dimensional Fund Advisors LP opened a new position with shares of PDL BioPharma Inc. (PDLI) during the lastest quarter, according to the public company’s latest Form 13F filing with the US Securities and Exchange Commission (SEC). This particular institutional investor became the owner of 9,603,719 shares of the Biotechnology provider’s common stock, which is currently worth approximately $30.25 million. According to the latest SEC filing from Dimensional Fund Advisors LP, the firm held approximately 8.43% of PDL BioPharma Inc.. On a separate note, BlackRock Fund Advisors entered a new position in PDL BioPharma Inc. stock during the lastest quarter, holdings valued at $28.49 million. Institutional investors and hedge funds hold 91.70% of this public company’s common stock.
Turning now to this publicly-traded company’s past performance, we will explore different moving trends for PDLI. This stock lost -1.62% during the last week and fall -22.32% over the last one-month period. Shares of this organization’s stock fall -9.46% throughout the last quarter. Within the last six months, the stock has increased 5.42%, with a full-year gain of 32.33%. At the time of writing, this stock’s year-to-date (YTD) price performance is now negative at -2.53%.
Out of a total of 1 brokerages that are currently covering PDL BioPharma Inc. (PDLI) stock, the average recommendation is “Hold” according to WSJ. 0 equities research analyst has rated the stock with a “Overweight” recommendation, 0 analysts have given this stock a “Buy” recommendation, 1 analysts have recommended that investors “Hold” this stock, and 0 analysts have given this stock a “Sell” rating and 0 suggested “Underweight”. Analysts’ average 1-year price target, among all the brokerages, is $2.78.
Shares of Halozyme Therapeutics Inc. (HALO) managed to reach a high of $29.13 and dropped down to a low of $28.26, before this stock settled at $28.27 at the end of the latest trading session. This organization’s stock has been displaying bearish momentum. Its Average True Range, or ATR, has fallen consistently after each of the most recent 14 trading sessions. Stock traders typically look at the ATR when they want to focus on technical analysis. At the time of writing, the 14-day ATR for Halozyme Therapeutics Inc. (HALO) is sitting at 0.95. Halozyme Therapeutics Inc. currently has a 52-week low of $12.71 with a 52-week high of $29.77. This organization has a debt-to-equity ratio of 3.69, a quick ratio of 17.30, and a current ratio of 19.20. This public company has a market cap of $3.78 billion, a beta of 1.60.
LaBarre Michael J., the SVP, Chief Technical Officer of Halozyme Therapeutics Inc. (HALO), sold 12,000 shares of Halozyme Therapeutics Inc. stock in an exchange that took place on Sep 21. The shares were sold at an average price of $26.91 each, amounting to a total Sale worth $322,884. As of the close of the Sale, the SVP, Chief Technical Officer now directly holds 158,800 shares of the organization’s stock, which is now worth about $4489276.0. The deal was disclosed in a Securities & Exchange Commission legal filing, which can be publicly viewed on the SEC website.
Halozyme Therapeutics Inc. (HALO) most recently publicly disclosed its earnings results on August 10, 2020. The organization posted $0.19 earnings per share (EPS) during the three-month period, which was -$0.06 lower than the consensus estimate of $0.25. The company experienced a negative return on equity of -31.70% and a negative net margin of -22.00%. Halozyme Therapeutics Inc. reported revenue of $180.50M during the last year. During the year-ago, the company reported -$0.27 EPS. Analysts forecast that Halozyme Therapeutics Inc. will report EPS of $0.2 for the current fiscal year.
Stock traders are taking a renewed look at shares of Halozyme Therapeutics Inc.. This stock’s current 14-day RSI is standing at 58.60%, with a 9-day RSI of 63.74%, and a 20-day RSI of 55.78%. The RSI, which stands for Relative Strength Index, is a widely-used oscillating indicator trusted by investors and traders alike. The RSI works within a range-bound space with values on a scale from 0 to 100. When the RSI line rises, the shares may be showing strength. The contrary is the case when the RSI line starts to fall. When using the RSI indicator, different time periods may be looked at. When using a shorter time frame, the RSI might be more volatile. A lot of traders keep their focus between the 30 and 70 marks on the RSI scale. A shift higher than 70 is widely-considered to demonstrate that the stock has entered overbought territory. Meanwhile, a drop below 30 indicates that it may be in oversold territory. Traders often use these levels to predict stock price reversals.